1
|
Handlogten MW, Bosley S, Dunn S, Zhu J, Lee-O'Brien A, Li L, Therres J, Chakrabarti L, Khanal B, Mowery R, Arumugam S, Klover J, Taleb M, Reier J, Hatton D, Schmelzer A. Accelerated cell culture process development and characterization for cilgavimab/tixagevimab (AZD7442) for the prevention and treatment of COVID-19. Biotechnol Bioeng 2023. [PMID: 36722717 DOI: 10.1002/bit.28336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 01/20/2023] [Accepted: 01/21/2023] [Indexed: 02/02/2023]
Abstract
The global COVID-19 pandemic ignited an unprecedented race to develop vaccines and antibody therapeutics. AstraZeneca's pursuit to provide AZD7442 (EVUSHELD), two long-acting, SARS-CoV-2 spike receptor binding domain-specific neutralizing monoclonal antibodies, to individuals at risk on highly accelerated timelines challenged our traditional ways of process development and spurred the rapid adoption of novel approaches. Conventional upstream development processes were replaced by agile strategies that combined technological advances and highly accelerated workflows. With calculated business risks and close cross-functional collaborations, this process paved the way for hyper accelerated antibody development from discovery through manufacturing, process validation, emergency use authorization filing, and global regulatory approvals. The result was initiation of commercial manufacturing at a contract manufacturing organization less than 6 months from the selection of cilgavimab and tixagevimab-a process that historically has taken close to 10 years.
Collapse
Affiliation(s)
- Michael W Handlogten
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Stefanie Bosley
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Sarah Dunn
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | - Jie Zhu
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Allison Lee-O'Brien
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Lina Li
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Jamy Therres
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Lina Chakrabarti
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Bijay Khanal
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Rachel Mowery
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Subhashini Arumugam
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Judith Klover
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Mohammed Taleb
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Jason Reier
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Diane Hatton
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | - Albert Schmelzer
- Cell Culture and Fermentation Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| |
Collapse
|
2
|
Handlogten MW, Lee-O'Brien A, Roy G, Levitskaya SV, Venkat R, Singh S, Ahuja S. Intracellular response to process optimization and impact on productivity and product aggregates for a high-titer CHO cell process. Biotechnol Bioeng 2017; 115:126-138. [DOI: 10.1002/bit.26460] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2017] [Revised: 08/19/2017] [Accepted: 09/19/2017] [Indexed: 12/24/2022]
Affiliation(s)
| | - Allison Lee-O'Brien
- Cell Culture and Fermentation Sciences; MedImmune LLC; Gaithersburg Maryland
| | - Gargi Roy
- Antibody Discovery and Protein Engineering; MedImmune LLC; Gaithersburg Maryland
| | | | - Raghavan Venkat
- Cell Culture and Fermentation Sciences; MedImmune LLC; Gaithersburg Maryland
| | - Shailendra Singh
- Biologics Development and Commercialization; West Point Pennsylvania
| | - Sanjeev Ahuja
- Cell Culture and Fermentation Sciences; MedImmune LLC; Gaithersburg Maryland
| |
Collapse
|